Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome

Inclusion Criteria:

Participants eligible for inclusion in this study must meet all of the following criteria:

1. Participants must have participated in the TWINSS core study, CCFZ533B2201 (NCT03905525), and must have completed the entire treatment period up to Week 48 andthe follow-up period up to Week 60

2. Signed informed consent must be obtained prior to participation in the Extensionstudy (i.e. before commencement of the Week 60 assessments of the core study)

3. In the judgement of the Investigator, participants must be expected to clinicallybenefit from continued iscalimab therapy

Exclusion Criteria:

Participants meeting any of the following criteria are not eligible for inclusion in this study.

1. Sjögren's Syndrome overlap syndromes where another autoimmune rheumatic diseaseconstitutes the principle illness, specifically:

• Moderate-to-severe active systemic lupus erythematosus (SLE) with anti-dsDNApositivity and renal involvement, or other organ involvement that impedes onability to score ESSDAI domains

• Active rheumatoid arthritis (RA) that impedes on the ability to score theESSDAI articular domain

• Systemic sclerosis

• Any other concurrent connective tissue disease (e.g., lupus nephritis (LN),large vessel vasculitis (LVV), Sharp syndrome (mixed connective tissue disease)that is active and requires immunosuppressive treatment outside the scope ofthis trial and would impede on Sjögren's Syndrome organ domain assessments

2. Use of other investigational drugs other than iscalimab during the core study

3. Active uncontrolled viral, bacterial or other infections requiring systemictreatment at the time of enrollment, or history of recurrent clinically significantinfection or of bacterial infections with encapsulated organisms

4. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of afemale after conception and until the termination of gestation, confirmed by apositive human Chorionic Gonadotropin (hCG) laboratory test

5. Women of child-bearing potential (WOCBP), defined as all women physiologicallycapable of becoming pregnant, unless they are using highly effective methods ofcontraception during dosing and for 14 weeks after stopping of investigational drug.

6. Missing ESSDAI (Cohort 1 and Cohort 2) or ESSPRI (Cohort 2) scores in the core studyat Weeks 0 and 4 or Weeks 40 and 48.